

Agenda for April 2026 Cancer Treatments Advisory Committee (CTAC) meeting

27 March 2026

Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its upcoming meeting in April 2026.

Applications

Alectinib ECOG status change

The Committee will discuss recent feedback and seek advice on widening access to alectinib for first line treatment of people with poorer Eastern Cooperative Oncology Group Performance Status (ECOG) being treated for non-small cell lung cancer (ALK-positive).

First line treatment for the group with a better ECOG status has been funded since 2019.

[Application for alectinib](#) for NSCLC (ALK positive) first line (funded)

[2019 funding decision](#)

Alectinib (branded as Alecensa) for non-small cell lung cancer (NSCLC)

The Committee will discuss an application for alectinib for people with resected (had surgery to remove the cancer), anaplastic lymphoma kinase-positive (ALK positive), non-small cell lung cancer (NSCLC).

[Application for alectinib \(Alecensa\)](#)

Durvalumab (branded as Imfinzi) for limited-stage, small cell lung cancer (LS-SMLC)

The Committee will discuss an application for durvalumab for people with limited stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy (CRT).

[Application for Durvalumab \(Imfinzi\)](#)

Inavolisib (branded as Itovebi) for breast cancer

The Committee will discuss an application for inavolisib for people with locally advanced or metastatic breast cancer, who have a PIK3K mutation, are HR-positive, and HER2-negative, following recurrence during or within 12 months of completing adjuvant therapy.

[Application for inavolisib \(Itovebi\)](#)

Ibrutinib (branded as Imbruvica) for mantle cell lymphoma

The Committee will discuss an application for ibrutinib for people with mantle cell lymphoma that are eligible for autologous stem cell transplant (ASCT). This is being considered as an alternative therapy to ASCT.

[Application for Ibrutinib \(Imbruvica\)](#)

Blinatumomab (branded as Blinctyo) for acute lymphoblastic leukaemia (ALL)

The Committee will discuss an application for blinatumomab for people with B cell lineage acute lymphoblastic leukaemia (ALL), who do not have measurable residual disease (MRD-negative).

[Application for Blinatumomab \(Blinctyo\)](#)

Advisory meeting agenda setting

We have six CTAC meetings scheduled in 2026 to help increase capacity for providing clinical advice on cancer funding applications.

The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.